Supplementary Table 1. Subgroup analyses for the effect of prolonged DAPT on the primary end point

Subgroup	Prolonged DAPT	Clopidogrel	HR (95% CI)	*P* value	*P* value for interaction
Age, yr					0.18
≥ 65	11/180	9/131	0.97 (0.40–2.35)	0.95	
< 65	6/191	1/135	1.49 (0.37–5.96)	0.57	
Acute coronary syndrome					0.19
Yes	11/178	5/131	1.76 (0.61–5.07)	0.30	
No	6/193	7/135	0.625 (0.22–1.94)	0.65	
STEMI					0.13
Yes	6/58	1/39	4.10 (0.49–34.06)	0.19	
No	11/313	11/227	0.72 (0.31–1.67)	0.45	
Diabetes					0.50
Yes	9/177	5/130	1.42 (0.48–4.24)	0.53	
No	8/194	7/136	0.87 (0.32–2.41)	0.80	
Chronic kidney disease					0.50
Yes	4/35	4/24	0.74 (0.19–2.98)	0.68	
No	13/336	8/242	1.28 (0.53–3.08)	0.59	
Total stent length ≥ 28 mm					0.95
Yes	7/171	7/165	1.08 (0.38–3.08)	0.89	
No	10/200	5/101	1.08 (0.37–3.16)	0.89	
Multivessel PCI					0.32
Yes	2/104	4/96	0.49 (0.09–2.69)	0.41	
No	15/267	8/170	1.31 (0.56–3.10)	0.53	
Everolimus stent					0.50
Yes	9/170	7/168	1.42 (0.53–3.80)	0.49	
Other DES	8/201	5/98	0.83 (0.27–2.54)	0.75	
Overall	371	266	0.87 (0.40–1.87)	0.71	



DAPT = dual antiplatelet therapy, STEMI = ST-segment elevation myocardial infarction, PCI = percutaneous coronary intervention, DES = drug-eluting stent, HR = hazard ratio, CI = confidence interval.